Every material Form 8-K Keros Therapeutics, Inc. has filed with the SEC since September 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Keros Therapeutics updated its corporate presentation for investor meetings and furnished it as Exhibit 99.1 to a Form 8-K filed November 5, 2026. The deck restates the company's pipeline, including the Takeda license for elritercept, which included a $200 million upfront payment, and timelines for rinvatercept trials in DMD and ALS.
Takeda paid Keros a $200 million upfront payment for global rights to elritercept, excluding mainland China, Hong Kong and Macau
Keros is eligible for milestone payments of over $1.1 billion under the Takeda agreement
Keros expects to report initial data from its Phase 2 DMD trial of rinvatercept in the first half of 2027
Keros plans to engage regulators on its ALS Phase 2 trial design in the second half of 2026
Keros Therapeutics reported net income of $14.2 million for the quarter ended September 30, 2026, compared with a net loss of $7.3 million in the same quarter of 2025. The increase was primarily due to $40.0 million of license revenue recognized under its Takeda license agreement. For the nine months, the company still posted a net loss of $38.3 million, and it said its cash will fund operations into the second half of 2028.
Q3 2026 total revenue was $40.0 million, up from $14.3 million in Q3 2025, driven by license revenue from Takeda.
Q3 2026 research and development expenses were $20.5 million and general and administrative expenses were $6.7 million.
Cash and cash equivalents were $259.5 million at September 30, 2026, down from $287.4 million at December 31, 2025.
Nine-month 2026 net loss was $38.3 million, compared with net income of $110.5 million in the first nine months of 2025.
Keros Therapeutics said it expects to receive a $20 million development milestone payment from partner Takeda after the first patient was dosed in the Phase 3 ELRiSE MF trial of elritercept. Keros expects to distribute 25% of the net cash proceeds from the payment to its stockholders after receipt.
$20 million development milestone payment under the elritercept license agreement with Takeda
Triggered by dosing of the first patient in the Phase 3 ELRiSE MF trial in myelofibrosis and anemia
Keros expects to distribute 25% of net cash proceeds from the payment to stockholders after receipt
Keros received a $200 million upfront payment in February 2025 and is eligible for milestones potentially exceeding $1.1 billion
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Keros Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →